BRIUMVI (ublituximab-xiiy)

Office-Administration – intravenous

Diagnosis considered for coverage:
  • Relapsing forms of Multiple Sclerosis: Indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults.
Coverage Criteria:
  • Diagnosis of a relapsing form of multiple sclerosis (MS) (e.g., clinically isolated syndrome, relapsing-remitting disease, secondary progressive disease, including active disease with new brain lesions), AND
    • One of the following:
      • Failure after a trial of at least 4 weeks, contraindication, or intolerance of at least two of the following disease-modifying therapies for MS:
      • Plegridy (peginterferon beta-1a) 
      • Avonex
      • Betaseron
      • Any one of the glatiramer acetate injections (e.g., Copaxone, Glatopa, generic glatiramer acetate) 
      • generic dimethyl fumarate
      • Gilenya, OR
    • For continuation of prior therapy, AND
  • Not used in combination with another disease-modifying therapy for MS, AND
  • Not used in combination with another B-cell targeted therapy (e.g., rituximab [Rituxan], belimumab [Benlysta], ofatumumab [Arzerra, Kesimpta]), AND
  • Not used in combination with another lymphocyte trafficking blocker (e.g., alemtuzumab [Lemtrada], mitoxantrone), AND
  • Prescribed by or in consultation with a neurologist
Reauthorization Criteria:
  • Documentation of positive clinical response to therapy (e.g., stability in radiologic disease activity, clinical relapses, disease progression), AND 
  • Not used in combination with another disease-modifying therapy for MS, AND 
  • Not used in combination with another B-cell targeted therapy (e.g., rituximab [Rituxan], belimumab [Benlysta], ofatumumab [Arzerra, Kesimpta]), AND
  • Not used in combination with another lymphocyte trafficking blocker (e.g., alemtuzumab [Lemtrada], mitoxantrone), AND
  • Prescribed by or in consultation with a neurologist
Dosing:
  • Initial dose is 150 mg IV infusion, followed 2 weeks later by 450 mg IV infusion. Maintenance is 450 mg IV infusion once every 24 weeks. 
  • Observe the patient for at least one hour after the completion of the first two infusions. Post-infusion monitoring of subsequent infusions is at physician discretion unless infusion reaction and/or hypersensitivity has been observed in association with the current or any prior infusion.
Coverage Duration:
  • Initial: 12 months
  • Reauthorization: 12 months
Authorization is not covered for the following:

The use of this drug for indications not listed in this policy does not meet the coverage criteria established by the Western Health Advantage (WHA) Pharmacy and Therapeutics (P&T) Committee.
 

Additional Information: 
  • According to the National MS Society, of the four disease courses that have been identified in MS, relapsing-remitting MS (RRMS) is characterized primarily by relapses, and secondary-progressive MS (SPMS) has both relapsing and progressive characteristics. These two constitute “relapsing forms of MS” if they describe a disease course that is characterized by the occurrence of relapses. The effectiveness of interferon beta in SPMS patients without relapses is uncertain. 
  • The advantage of using combination disease-modifying therapy (DMT) compared to monotherapy DMT use has not been demonstrated, but there are safety concerns, such as reduced efficacy or disease aggravation, with combination use. 
Policy Updates:
  • 08/15/2023 – New policy approved by P&T.
References:
  1. Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline: Disease-modifying therapies for adults with multiple sclerosis. Neurology 2018;90:777-788. 
  2. National Multiple Sclerosis Society. Types of MS. Available at: https://www.nationalmssociety.org/What-is-MS/Types-of-MS. Accessed March 29, 2019. 
  3. Mavenclad Prescribing Information. EMD Serono, Inc. Rockland, MA. April 2019. 
  4. Wingerchuk, D., & Carter, J. (2014). Multiple Sclerosis: Current and Emerging Disease-Modifying Therapies and Treatment Strategies. Mayo Clinic Proceedings, 89(2), 225-240. 
  5. Sorensen, P., Lycke, J., Erälinna, J., Edland, A., Wu, X., & Frederiksen, J. et al. (2011). Simvastatin as add-on therapy to interferon beta-1a for relapsing-remitting multiple sclerosis (SIMCOMBIN study): a placebo-controlled randomised phase 4 trial. The Lancet Neurology, 10(8), 691-701. 
  6. Briumvi Prescribing Information. TG Therapeutics, Inc. Morrisville, NC. December 2022. 

Last review date: September 1, 2023

Rite Aid Pharmacy Patients: All Rite Aid pharmacies nationwide are closing! Please be on the lookout for information from Rite Aid pharmacies about their bankruptcy and store closures. Call your Rite Aid pharmacy for questions about your prescriptions and new pharmacy options. WHA is here to help as well. Contact Us via Phone